Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego Health : Episode 6

Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

June 11, 2024

By Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Steven Edelman, MD

Opinion

Video

Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.

EP: 1.Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners

EP: 2.The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages

EP: 3.The Crucial Impact of Early Intervention in Preventing T1D Stage Progression

EP: 4.Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

EP: 5.Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities

Now Viewing

EP: 6.Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

EP: 7.Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights

EP: 8.Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement

EP: 9.Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!